ProBiotix Health Past Earnings Performance
Past criteria checks 0/6
ProBiotix Health's earnings have been declining at an average annual rate of -26.3%, while the Biotechs industry saw earnings growing at 7.7% annually. Revenues have been growing at an average rate of 55.1% per year.
Key information
-26.3%
Earnings growth rate
-21.3%
EPS growth rate
| Biotechs Industry Growth | -14.6% |
| Revenue growth rate | 55.1% |
| Return on equity | -38.8% |
| Net Margin | -23.3% |
| Last Earnings Update | 30 Jun 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How ProBiotix Health makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 24 | 2 | 0 | 2 | 0 |
| 31 Mar 24 | 2 | -1 | 2 | 0 |
| 31 Dec 23 | 2 | -1 | 2 | 0 |
| 30 Jun 23 | 1 | 0 | 1 | 0 |
| 31 Mar 23 | 1 | 0 | 1 | 0 |
| 31 Dec 22 | 1 | 0 | 1 | 0 |
| 30 Jun 22 | 1 | 0 | 1 | 0 |
| 31 Mar 22 | 1 | 0 | 1 | 0 |
| 31 Dec 21 | 1 | 0 | 0 | 0 |
| 31 Dec 20 | 1 | 0 | 0 | 0 |
| 31 Dec 19 | 0 | -1 | 0 | 0 |
Quality Earnings: X90 is currently unprofitable.
Growing Profit Margin: X90 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: X90 is unprofitable, and losses have increased over the past 5 years at a rate of 26.3% per year.
Accelerating Growth: Unable to compare X90's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: X90 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-18.2%).
Return on Equity
High ROE: X90 has a negative Return on Equity (-38.75%), as it is currently unprofitable.